Clinical Trial Update: Time-limited Triplet Combination of Pirtobrutinib, Venetoclax, and Obinutuzumab for Patients With Treatment-naïve Chronic Lymphocytic Leukemia (CLL) or Richter Transformation (RT) [Phase 2]

View source ↗

Summary

A Phase 2 clinical trial is evaluating a time-limited triplet therapy of pirtobrutinib, venetoclax, and obinutuzumab for treatment-naïve chronic lymphocytic leu…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Chronic Lymphocytic Leukemia
• Richter Transformation

Drugs mentioned

• Obinutuzumab (obinutuzumab)
• Pirtobrutinib (pirtobrutinib)
• Venetoclax (venetoclax)

Snippet

Sponsor: M.D. Anderson Cancer Center | Conditions: Leukemia | Phase 2 | Status: RECRUITING